thanks for this. Eclectic find. Shows very clearly why one should be cautious. We also don’t know if any of the M12 had diabetes, were obese, were over 80 or had hyper tension. We know damn well the broader population statistics would include those and that lowers the chance of survival significantly.
the control is critical given underlying health factors play a big part in chances of survival.
- Forums
- ASX - By Stock
- Cell Therapy News/Articles
thanks for this. Eclectic find. Shows very clearly why one...
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.52 |
Change
0.055(3.77%) |
Mkt cap ! $1.729B |
Open | High | Low | Value | Volume |
$1.48 | $1.54 | $1.45 | $6.072M | 4.049M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5951 | $1.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.52 | 133644 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5951 | 1.515 |
2 | 25946 | 1.510 |
3 | 69790 | 1.505 |
10 | 85830 | 1.500 |
5 | 49557 | 1.495 |
Price($) | Vol. | No. |
---|---|---|
1.520 | 133644 | 5 |
1.525 | 36900 | 5 |
1.530 | 108768 | 5 |
1.535 | 48010 | 6 |
1.540 | 113241 | 11 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online